|Healthcare Review: WebMD, Almost Family, Ariad Pharmaceuticals, Snyta Pharmaceuticals, Akebia Therapeutics|
|By Staff and Wire Reports|
|Wednesday, 06 August 2014 14:02|
By next week, WebMD ($WBMD) will make a tender offer for up to 2M shares of its common stock at a price of $48.50 per share. The BOD decided to execute the offer in order to provide liquidity to stockholders. The buyback represents ~5.1% of the outstanding shares of the firm.
Almost Family ($AFAM) Q2 results: Revenues: $124.9M (+44.6%); Gross Margin: $59.4M (+47.4%); Operating Expenses: $52.3M (+46.1%); Operating Income: $7.0M (+59.1M); Net Income: $4.1M (+57.3%); EPS: $0.42 (+55.6%); Quick Assets: $2.8M (-77.0%); Cash Burn: ($1.9M) (-134.7%).
Ariad Pharmaceuticals (NASDAQ:ARIA) Q2 results: Total Revenues: $14.0M (+82.3%), Net Product Sales: $12.1M (+82.3%); Operating Expenses: $68.4M (-17.6%); Net Loss: ($56.9M) (+17.5%); Loss Per Share: ($0.30) (+18.9%); Quick Assets: $310.0M (+30.7%); Cash Burn: ($95.0M) (+16.7%).
Snyta Pharmaceuticals (NASDAQ:SNTA) Q2 results: Revenues: $0; Operating Expenses: $21.7M (-1.8%); Operating Loss: ($21.7M) (+1.8%); Net Loss: ($22.3M) (+2.2%); Loss Per Share: ($0.24) (+27.3%); Quick Assets: $112.1M (+22.5%).
Akebia Therapeutics (NASDAQ:AKBA) appoints Brad Maroni, M.D., as SVP and Chief Medical Officer. He joins the firm from Biogen where he was VP, Medical Research. The company also hires Mark De Rosch, Ph.D., as VP of Regulatory Affairs and Tamara Dillion as VP of Human Resources.